Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia Genetics
Reports by M. Raponi and co-researchers describe recent advances in acute myeloid leukemia genetics
April 13th, 2008
Scientists discuss in 'A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia' new findings in acute myeloid leukemia. According to recent research from the United States, "At present, there is no method available to predict response to farnesyltransferase inhibitors (FTIs). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib in older adults with previously untreated acute myeloid leukemia (AML)." "The RASGRP1/APTX gene expression ratio was found to predict response to tipifarnib with the greatest accuracy using a 'leave one out' cross validation...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
